DermTech Announces the Publication of a Health Economic and Utility Study of the PLA in JAMA Dermatology

Published: Jul 11, 2018

LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the publication of “Economic Implications of a Non-Invasive Molecular Pathology Assay for Pigmented Skin Lesions” by John Hornberger MD and Daniel M. Siegel MD in JAMA Dermatology. The purpose of the study was to assess the cost implications of using the pigmented lesion assay gene expression test using real-world utility data versus the current pathway of visual assessment followed by biopsy and histopathologic assessment. This cost savings analysis demonstrated the PLA reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. Cost reductions of $400-$600 per assessed pigmented lesion was achievable vs. the current histopathologic standard of care, based on typical reimbursement rates for the PLA. Savings were primarily driven by reduction in initial surgical biopsies and excisions and reduced stage-related treatment costs from missing fewer melanomas.

“The increasing strain on our healthcare system and the need for cutting edge technologies our patients deserve, to help detect melanoma early when the prognosis is excellent, highlight the value of the pigmented lesion assay. This test transforms the current pathway of diagnosing melanomas from one that is invasive and subjective to one that is non-invasive, objective, more accurate and significantly cheaper. Cost savings are important, but finding melanoma early is priceless,” said study author Dr. Daniel Siegel, a leading dermatologist, health economics expert and former president of the American Academy of Dermatology.

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit dermtech.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005548/en/

Contacts

DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
858-450-4222
sdion@dermtech.com

 

Source: DermTech

Back to news